Structured rehabilitation held handgrip strength through chemoradiotherapy

Design

Prospective multicentre randomised open-label phase 2 trial

Population

111 patients with abdominal malignancy starting concurrent chemoradiotherapy: 57 rehabilitation, 54 standard care

Primary outcome

Handgrip strength at the end of chemoradiotherapy, adjusted for baseline

Effect

Adjusted mean difference 4.87 kg (95% CI 3.36-6.38, P<.001); 83.9% met exercise targets; exploratory gains in body weight, skeletal muscle mass, albumin, prealbumin, nutritional and psychological scores, and lower haematological toxicity, all surviving false discovery rate correction

Concurrent chemoradiotherapy for abdominal cancer reliably costs patients muscle, weight and nutritional reserve, and the loss predicts how much treatment they can complete. This phase 2 trial randomised 111 patients starting chemoradiotherapy to a multidisciplinary mHealth rehabilitation programme — delivered by a dedicated team through an app with wearable heart rate monitoring — or to standard care.

Adherence was high: 83.9% met their exercise targets, which is notable in a population undergoing chemoradiotherapy. The primary endpoint, handgrip strength at the end of treatment adjusted for baseline, was 4.87 kg higher in the intervention group (95% CI 3.36-6.38). Secondary endpoints, all exploratory, moved the same way: body weight, skeletal muscle mass, albumin, prealbumin, nutritional scores, psychological measures, and rates of haematological toxicity, all remaining significant after false discovery rate correction.

The caveats are the authors' own and they are substantial. The trial was open-label, so patients knew which arm they were in and handgrip strength is effort-dependent. Tumour types were heterogeneous. Follow-up was short and no survival or treatment-completion outcome is reported. What it establishes is that a structured programme is deliverable during chemoradiotherapy with good adherence and moves physiological measures — which is the case for a phase 3 trial, not for changing practice.

• Phase 2 and open-label; not a reason to commission a programme yet
• Handgrip strength is effort-dependent and the trial was unblinded
• Adherence of 83.9% during chemoradiotherapy is the most transferable finding
• No treatment completion, survival or long-term outcome was reported
• Where a service already offers rehabilitation, this supports continuing rather than expanding it

Why it matters

It shows the intervention is deliverable and adhered to in the group usually considered too unwell to exercise.

Don't overread it

Open-label phase 2 with an effort-dependent primary endpoint and exploratory secondary outcomes; no clinical outcome was measured.

The statistics, in plain English

A 4.87 kg difference in handgrip is large relative to typical adult values, which should raise rather than settle suspicion in an open-label trial where the measurement depends on how hard the patient tries. The secondary endpoints were exploratory and analysed without multiplicity adjustment; the authors' false discovery rate sensitivity analysis is the right response and they report it honestly, but it does not convert exploratory findings into confirmatory ones.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.